Tuesday, 22 Oct 2019

You are here

FDA REMS/Safety Panel Backs Educational Requirements for Opioid Prescribers

An advisory panel to the Food and Drug Administration met May 3rd and 4th to review whether the long-acting or extended release (ER/LA) opioid REMS programs approved in 2012 have had a meaningful effect on the opioid abuse problems noted nationwide. The FDA panel voted overwhelmingly to endorse required training for doctors who prescribe opioid painkillers.
 
The manufacturers of ER/LA opioids pooled their resources to form the REMS Program Companies (RPC) (23 companies) to fund, develop and implement educational programs regarding the safe use of ER/LA opioids - as mandated in the current REMS requirement.

The FDA advisory committee recommendation followed a two-day hearing on the medical evidence regarding opioids and ways to improve their safety. The committee acted after hearing extensive public testimony that making opioid training mandatory for doctors was important, and that it shouldn’t be controlled by the drug industry.

While there was some evidence that the roll-out of these educational programs was associated with decreasing rates of abuse, overdose and death, these also came at a time of downward trends in prescribing and overdose after 2010, when other strategies were in place to address the opioid abuse problem.

There was discussion on how to enhance the CME education offerings, including better access and streamlined online training.  

As this was an advisory hearing, no formal policies were established and the FDA will take the recommendations into account during their deliberations.

 

Add new comment

More Like This

Joint Injections: Are They Worth the Risk?

Intra-articular injections of corticosteroids for relief of the pain of hip or knee osteoarthritis (OA) may have adverse long-term consequences, researchers suggested.

Hydroxychloroquine Blood Levels May Predict Future Retinopathy

A study of 527 patients receiving daily hydroxychloroquine (HCQ) concluded that hydroxychloroquine blood levels may predict future HCQ retinopathy.

This study assessed whether lower HCQ dosing, as recommended by the 2016 American Academy of Ophthalmology (AAO) guidelines (less than 5 mg/kg), would favorably affect retinopathy outcomes.

Arthritis Foundation Releases First CBD Guidance for Adults With Arthritis

As the leading organization for people with arthritis, the Arthritis Foundation has just released the first CBD guidance for adults with arthritis. CBD, or cannabidiol, a plant-based compound, has become popular among people with arthritis seeking to ease chronic joint pain.

Persistent Inflammatory Arthritis After Immune Checkpoint Inhibitors

Braaten and colleagues from Johns Hopkins School of Medicine have reported their experience with chronic inflammatory arthritis induced by immune checkpoint inhibitor therapies, showing that in some, inflammatory arthritis persists after the immunotherapy has been discontinued.

Checkpoint Inhibitors: Who Gets Myocarditis?

The usual risk factors for myocarditis may not apply to who gets it while on immune checkpoint inhibiting cancer drugs, an FDA adverse event database suggested.